Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1739410 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $15.96Day −1.21%Mkt cap $85M1Y +324.5%Off 52W high −9.2%Vol (1Y) 94.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,251 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.2% of sh out |
| Days to cover3.5d |
| Top-10 13F concentration82.7% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$858,000 |
| Earnings (TTM)-$7.8M |
| ROE−15.0% |
| Net margin−1046.4% |
| ROIC−70.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+190.8% |
| 1Y+324.5% |
| 3Y−66.6% |
| Since incept. (ann.)−34.9% |
Total return through 2026-07-29 · series begins 2021-07-30. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)94.0% |
| Ann. volatility (3Y)110.6% |
| Sharpe (1Y)1.89 |
| Sharpe (3Y)0.17 |
| Max drawdown (1Y)−31.1% |
| Max drawdown (3Y)−95.8% |
| Beta (3Y vs SPY)0.72 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 793,451 | $7M | 14.98% | −53.2% |
| VIKING GLOBAL INVESTORS LP | 524,347 | $5M | 9.90% | −87.5% |
| Cormorant Asset Management, LP | 400,000 | $4M | 7.55% | new |
| TPG GP A, LLC | 378,551 | $3M | 7.14% | −87.5% |
| Balyasny Asset Management L.P. | 376,573 | $3M | 7.11% | new |
| Laurion Capital Management LP | 302,756 | $3M | 5.71% | new |
| Nantahala Capital Management, LLC | 300,635 | $3M | 5.67% | new |
| Pivotal bioVenture Partners Investment Advisor LLC | 300,579 | $3M | 5.67% | −87.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$1.46 | — | $212,000 | +0.0% |
| 2025-12-31 | 2026-03-16 | — | — | $222,000 | +484.2% |
| 2025-09-30 | 2025-11-06 | — | — | $212,000 | −29.1% |
| 2025-06-30 | 2025-08-07 | — | — | $212,000 | −29.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
